Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash & Equivalents: 2020-2025

Historic Revenue - Interest and Investment Income for Cellebrite DI (CLBT) over the last 1 years, with Jun 2024 value amounting to $556.6 million.

  • Cellebrite DI's Cash & Equivalents rose 106.35% to $281.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.4 million, marking a year-over-year increase of 106.35%. This contributed to the annual value of $191.7 million for FY2024, which is 1.13% up from last year.
  • Per Cellebrite DI's latest filing, its Cash & Equivalents stood at $281.4 million for Q3 2025, which was up 56.99% from $179.2 million recorded in Q2 2025.
  • In the past 5 years, Cellebrite DI's Cash & Equivalents ranged from a high of $281.4 million in Q3 2025 and a low of $84.6 million during Q3 2022.
  • Its 3-year average for Cash & Equivalents is $149.5 million, with a median of $136.3 million in 2024.
  • Data for Cellebrite DI's Revenue - Interest and Investment Income shows a peak YoY skyrocketed of 32.13% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Cellebrite DI's Revenue - Interest and Investment Income stood at $339.8 million in 2021, then rose by 18.69% to $403.3 million in 2022, then surged by 32.13% to $532.9 million in 2023, then reached $556.6 million in 2024.
  • Its Cash & Equivalents stands at $281.4 million for Q3 2025, versus $179.2 million for Q2 2025 and $90.5 million for Q1 2025.